IMMUNIC, INC. (IMUX): Form 8-K filed 2026-11-13

Accepted by EDGAR: 2026-11-13 08:00 ET
Event date: 2026-11-13
Accession no.: 0001493152-26-051543
Original filing: SEC EDGAR filing index

AI summary of the filing text. It can contain mistakes; the original filing is authoritative.

Immunic reports third quarter 2026 results and updates Phase 3 trial timelines

Immunic reported a net loss of approximately $42.3 million for the three months ended September 30, 2026, compared with approximately $25.6 million in the prior-year period. Cash and cash equivalents were $132.0 million, expected to fund operations into late 2027. The company expects top-line data from its Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis in December 2026.

Net loss for the three months ended September 30, 2026 was approximately $42.3 million, or $0.99 per basic and diluted share.
Cash and cash equivalents were $132.0 million as of September 30, 2026; Immunic expects funding to last into late 2027.
Top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials are expected in December 2026.
First-patient-enrolled in the Phase 3 PROTECT-MS trial is expected in the first half of 2027.

earningsproductguidance

Items reported

Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed".
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Documents

Type	Description	Document
8-K	8-K	form8-k.htm
EX-99.1	EX-99.1	ex99-1.htm

The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.